Skip to main content
Barbra Dickerman on Muck Rack

Barbra Dickerman

As seen in: Nature, Wiley Online Library, JAMA (The Journal of the American Medical Association), UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbra

Contact Barbra, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The TARGET guideline for reporting observational studies of interventions

|
By Harrison J. Hansford, James McAuley, Sonja A. Swanson Verified, Nazrul Islam, Issa J. Dahabreh, Barbra Dickerman, Matthias Egger, Xabier García-Albéniz, Robert M. Golub, Sara Lodi, Margarita Moreno-Betancur, Sallie-Anne Pearson, Sebastian Schneeweiss, Jonathan A. C. Sterne, Melissa Sharp, Matthew Jones, Elizabeth Stuart, Hopin Lee, Miguel A. Hernán, Aidan Cashin
| Nature Verified
Observational (non-experimental) studies of interventions can generate valuable evidence when randomized trials are infeasible, unethical or unable to provide timely answers to important clinical and policy questions. The use of observational data to estimate the comparative benefits and harms of medical interventions has increased substantially and has informed clinical, policy and regulatory decisions1,2.
Open in Who Shared Issue with article?

Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans - Nature Microbiology

|
By Barbra Dickerman, Hanna Gerlovin, Arin L. Madenci, David R. Gagnon
| Nature Verified
Abstract Vaccination against SARS-CoV-2 has been effective in reducing the burden of severe disease and death from COVID-19. Third doses of mRNA-based vaccines have provided a way to address waning immunity and broaden protection against emerging SARS-CoV-2 variants. However, their comparative effectiveness for a range of COVID-19 outcomes across diverse populations is unknown.
Open in Who Shared Issue with article?

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans

|
By Barbra Dickerman, Arin L. Madenci, Hanna Gerlovin, Katherine E. Kurgansky
| JAMA (The Journal of the American Medical Association) Verified
Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans | Vaccination | JAMA Internal Medicine | JAMA Network [Skip to Navigation] Figure. Selection of Persons for the Emulation of a Target Trial Evaluating the Comparative Safety of the BNT162b2 and mRNA-1273 Vaccines (January 4 to October 5, 2021) BMI indicates body mass index; VA, US Department of Veterans Affairs. Table 1.
Open in Who Shared Issue with article?
See all 15 articles